Phase 3 Recruiting NIH
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarc…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06422806
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in North Carolina: - Mission Hospital — Asheville, North Carolina
- Duke University Medical Center — Durham, North Carolina
- East Carolina University — Greenville, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Novant Health Presbyterian Medical Center — Charlotte, North Carolina
- Duke University Medical Center — Durham, North Carolina
- East Carolina University — Greenville, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 3 Recruiting Network
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…
Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Novant Health Presbyterian Medical Center — Charlotte, North Carolina
- Duke University Medical Center — Durham, North Carolina
- East Carolina University — Greenville, North Carolina
Phase 3 Recruiting Network
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyos…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
NCT ID: NCT04031677
Sites in North Carolina: - Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Duke University Medical Center — Durham, North Carolina
Phase 3 Recruiting Industry
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Sponsor: Polaris Group
NCT ID: NCT05712694
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in North Carolina: - Local Institution - 2144 — Goldsboro, North Carolina
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in North Carolina: - Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people wi…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05634369
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
- Levine Cancer Institute — Charlotte, North Carolina
- Duke Children's Hospital/Duke Health — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in North Carolina: - Levine Children's Hospital- Pediatric Neuro-Oncology — Charlotte, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Sponsor: USWM CT, LLC
NCT ID: NCT05642455
Sites in North Carolina: - Duke University School of Medicine — Durham, North Carolina
Phase 1, Phase 2 Recruiting Academic/Other
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational intervention. Phase I studies also try to define the appropriate dose of the investigational therapy to use for further studies.…
Sponsor: Massachusetts General Hospital
NCT ID: NCT01659203
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting Academic/Other
The purpose of this research study is to see how metformin, when used in combination with standard of care (SOC) treatment for metastatic (cancer that has spread) soft tissue sarcoma can improve patient outcomes.
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT07291297
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 1 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in North Carolina: - Duke Blood Cancer Center — Durham, North Carolina
Phase 1 Recruiting Industry
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05245500
Sites in North Carolina: - University of North Carolina - Gastroenterology and Hepatology — Chapel Hill, North Carolina
- University of North Carolina — Chapel Hill, North Carolina
Phase 1 Recruiting Academic/Other
This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that a…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT07194044
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
- Levine Cancer Institute — Charlotte, North Carolina
Phase 1 Recruiting Industry
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies
Sponsor: Poseida Therapeutics, Inc.
NCT ID: NCT06014762
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
EARLY Phase 1 Recruiting Industry
This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via …
Sponsor: Presage Biosciences
NCT ID: NCT04541108
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 1 Recruiting Industry
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neu…
Sponsor: Valent Technologies, LLC
NCT ID: NCT04337177
Sites in North Carolina: - University of North Carolina at Chapel Hill - North Carolina Cancer Hospital — Chapel Hill, North Carolina
- Atrium Health Levine Children's Hospital - Carolinas Medical Center — Charlotte, North Carolina
- Duke University Children's Hospital and Health Center — Durham, North Carolina
Phase 1 Recruiting Industry
In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to estab…
Sponsor: Immunolight, LLC
NCT ID: NCT04389281
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
- Duke University — Durham, North Carolina
Phase 1 Recruiting Academic/Other
The body has different ways of fighting infections and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are molecules that fig…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT03721068
Sites in North Carolina: - Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill, North Carolina
Phase 1 Recruiting Academic/Other
Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to rise, in part due to the obesity epidemic. Obese women with EC have a 6.3-fold increased risk…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT05542407
Sites in North Carolina: - Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in North Carolina: - AdventHealth Infusion Center Asheville — Asheville, North Carolina
- UNC Health Cancer Care Cary — Cary, North Carolina
- Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
- AdventHealth Infusion Center Haywood — Clyde, North Carolina
- Durham VA Medical Center — Durham, North Carolina
NA Recruiting Network
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in North Carolina: - CaroMont Regional Medical Center — Gastonia, North Carolina
- CaroMont Health - Lincoln Cancer Center — Lincolnton, North Carolina
Recruiting Network
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hyd…
Sponsor: Children's Oncology Group
NCT ID: NCT01790152
Sites in North Carolina: - Mission Hospital — Asheville, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina